Skip to main content

Table 1 Comparison of the demographic and clinical characteristics between multiple sclerosis (MS) patients and non-MS controls in the merged dataset and in the validation group

From: N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis

 

Datasets

Validation

MS (n = 61)

Non-MS (31)

P

MS (n = 11)

Non-MS (n = 3)

P

Age (years)

44.87 ± 15.66

42.71 ± 12.00

0.466

29.73 ± 10.78

42.33 ± 11.85

0.195

Sex (%)

 Female

37 (60.7%)

19 (61.3%)

0.953

8 (72.7%)

2 (66.7%)

0.837

 Male

24 (39.3%)

12 (38.7%)

 

3 (27.3%)

1 (33.3%)

 

Subtype (%)

 RRMS

32 (52.5%)

–

–

8 (72.7%)

–

–

 PPMS

10 (16.4%)

–

 

1 (9.1%)

–

 

 SPMS

19 (31.1%)

–

 

2 (18.2%)

–

 

DMDs (%)

–

–

–

3 (27.3%)

–

–

CSF testing

 OB (%)

–

–

–

1 (16.7%)

–

–

 Antibody (%) (anti-AQP4, MOG, MBP)

   

0 (0.0%)

  
  1. In the validation group, six of the 11 MS patients underwent CSF OB testing, and only one patient found positive result. Nine of them measured related antibodies while all reported negative results